A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas

Condition:   Advanced Solid Tumors or Lymphomas
Intervention:   Drug: CA-170
Sponsor:   Curis, Inc.
Recruiting - verified June 2016

from #ENT via xlomafota13 on Inoreader http://ift.tt/28RUafT
via IFTTT